WilliamENovotnyMD
Pediatrics • Greenville, NCPediatric Critical Care Medicine, Adolescent Medicine
Brody School of Medicine
Dr. Novotny is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2150 Herbert Ct
Greenville, NC 27834Phone+1 252-744-5437Fax+1 252-744-1514
Education & Training
Sparrow HospitalResidency, Pediatrics, 1984 - 1985
St Louis University School of MedicineInternship, Transitional Year, 1981 - 1982
The University of Toledo College of MedicineClass of 1981
Certifications & Licensure
NC State Medical License 1993 - 2025
OH State Medical License 1994 - 1996
NY State Medical License 1989 - 1994
MI State Medical License 1984 - 1990- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Critical Care Medicine
Clinical Trials
- The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Start of enrollment: 2020 Jul 29
- Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Start of enrollment: 2020 Nov 15
Publications & Presentations
PubMed
- The potential effect of metabolic alkalosis on insulin sensitivity in an adolescent with new‐onset type 1 diabetesWilliam E Novotny, Irma Fiordalisi, Cynthia P Keel, Glenn D. Harris
Clinical Case Reports. 2021-05-01 - Why humans should not eat broom straws: Pericarditis and endocarditis.William E Novotny, Cynthia P Keel
Annals of Pediatric Cardiology. 2020-05-01 - 48 citationsPhysical Rehabilitation in Critically Ill Children: A Multicenter Point Prevalence Study in the United States.Sapna R. Kudchadkar, Archana Nelliot, Ronke Awojoodu, Dhananjay Vaidya, Chani Traube
Critical Care Medicine. 2020-05-01
Lectures
- Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-) in Patients with Mantle Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
